biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.54% year-on-year.
Undervalued
The company’s latest PE is 3.61, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.49M shares, decreasing 13.59% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.42M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.51.